A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States

The process of clinical development and regulatory review of new therapeutics in the United States was significantly changed by a number of legislative acts passed in the 1980s and 1990s. These acts were designed to encourage the development of innovative products, especially for rare, serious or life-threatening diseases, and to ensure that patients had timely access to these treatments. To assess the effects of the various modifications to the process, the Tufts Center for the Study of Drug Development analysed clinical development and approval data for 554 therapeutics (504 small molecules, 40 recombinant proteins and 10 monoclonal antibodies) approved in the United States from 1980–2001. Trends in the number of approved products and the clinical development and approval times indicated that the effects of these changes were generally beneficial as of the mid- to late-1990s, but that the gains have not been sustained in the early 2000s. Current efforts by the FDA, and the pharmaceutical and biopharmaceutical industry, to reverse the recent tendency toward fewer new approvals and longer approval times are discussed.

[1]  L. Lasagna,et al.  Trends in Drug Development: The 1985‐86 New Drug Approvals , 1987, Journal of clinical pharmacology.

[2]  K. Kaitin,et al.  THE NEW DRUG APPROVALS OF 1993, 1994, AND 1995: TRENDS IN DRUG DEVELOPMENT , 1997, American journal of therapeutics.

[3]  L. Lasagna,et al.  The New Drug Approvals of 1990, 1991, and 1992: Trends in Drug Development , 1994, Journal of clinical pharmacology.

[4]  E. M. Healy,et al.  The New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee Era* , 2000 .

[5]  C. Milne Orphan products—pain relief for clinical development headaches , 2002, Nature Biotechnology.

[6]  C. Milne,et al.  Fast Track Product Designation under the Food and Drug Administration Modernization Act: The Industry Experience , 2001 .

[7]  J. Reichert,et al.  Therapeutic recombinant proteins: trends in US approvals 1982 to 2002. , 2003, Current opinion in molecular therapeutics.

[8]  Janice M Reichert,et al.  Therapeutic monoclonal antibodies: trends in development and approval in the US. , 2002, Current opinion in molecular therapeutics.

[9]  J. DiMasi New drug development in the United States from 1963 to 1999 , 2001, Clinical pharmacology and therapeutics.

[10]  L. Lasagna,et al.  The New Drug Approvals of 1987, 1988, and 1989: Trends in Drug Development , 1991, Journal of clinical pharmacology.

[11]  L Lasagna,et al.  The development and regulation of new medications. , 1978, Science.

[12]  K. Kaitin,et al.  The New Drug Approvals of 1999, 2000, and 2001: Drug Development Trends a Decade after Passage of the Prescription Drug User Fee Act of 1992 , 2003 .